Generic Xalkori Availability
XALKORI (crizotinib - capsule;oral)
Manufacturer: PF PRISM CV
Approval date: August 26, 2011
Strength(s): 200MG, 250MG [RLD]
Has a generic version of Xalkori been approved?
No. There is currently no therapeutically equivalent version of Xalkori available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xalkori. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Aminoheteroaryl compounds as protein kinase inhibitors
Issued: June 12, 2007
Inventor(s): Cui; Jingrong Jean & Bhumralkar; Dilip & Botrous; Iriny & Chu; Ji Yu & Funk; Lee A. & Hanau; Cathleen Elizabeth & Harris; G. Davis & Jia; Lei & Johnson; Joanne & Kolodziej; Stephen A. & Kung; Pei-Pei & Li; Xiaoyuan (Sharon) & Lin; Jason (Qishen) & Meng; Jerry Jialun & Nambu; Mitchel
Assignee(s): Sugen, Inc.
Aminopyridine and aminopyrazine compounds of formula (1), compositions including these compounds, and methods of their use are provided. Preferred compounds of formula 1 have activity as protein kinase inhibitors, including as inhibitors of c-METPatent expiration dates:
- March 1, 2025✓
- March 1, 2025
Method of treating abnormal cell growth
Issued: November 2, 2010
Inventor(s): Christensen; James Gail & Zou; Yahong
Assignee(s): Pfizer Inc.
The present invention relates to the use of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, a novel c-Met/HGFR inhibitor, for treating abnormal cell growth in mammals. In particular, the invention provides methods of treating mammals suffering from cancer.Patent expiration dates:
- May 12, 2027✓
- May 12, 2027
Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
Issued: December 28, 2010
Inventor(s): Cui; Jingrong Jean & Funk; Lee Andrew & Jia; Lei & Kung; Pei-Pei & Meng; Jerry Jialun & Nambu; Mitchell David & Pairish; Mason Alan & Shen; Hong & Tran-Dube; Michelle
Assignee(s): Agouron Pharmaceuticals, Inc.
Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.Patent expiration dates:
- October 8, 2029✓✓
- October 8, 2029
Polymorphs of a c-MET/HGFR inhibitor
Issued: July 10, 2012
Inventor(s): Cui; Jingrong Jean & Tran-Dubé; Michelle Bich
Assignee(s): Pfizer Inc.
This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.Patent expiration dates:
- November 6, 2029✓✓
- November 6, 2029
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- August 26, 2016 - NEW CHEMICAL ENTITY
- August 26, 2018 - ORPHAN DRUG EXCLUSIVITY
- Xalkori Consumer Information (Drugs.com)
- Xalkori Consumer Information (Wolters Kluwer)
- Xalkori Consumer Information (Cerner Multum)
- Xalkori Advanced Consumer Information (Micromedex)
- Xalkori AHFS DI Monographs (ASHP)
- Crizotinib Consumer Information (Wolters Kluwer)
- Crizotinib Consumer Information (Cerner Multum)
- Crizotinib Advanced Consumer Information (Micromedex)
- Crizotinib AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|